The historic rise of Viagra has consistently remained a example of pharmaceutical success, however its legacy within the broader sector now raises questions about long-term gains. Copycat versions are eroding exclusivity , leading to worries that investing in companies heavily reliant to Viagra's previous position could be a problematic strategy, e